HIV 17 Glasgow 2024

ART pipeline 2025: exciting dual long-acting combinations and the challenge of generic dolutegravir

1 January 2025. Related: Special reports, Conference reports, Pipeline report, Antiretrovirals.

Glasgow HIV Congress 2024: Introduction and links

26 November 2024. Related: Conference reports.

Once-weekly oral ART with islatravir plus lenacapavir sustains results to week 48

26 November 2024. Related: Conference reports, Antiretrovirals.

EACS guidelines: New format and contents includes chemsex

26 November 2024. Related: Conference reports, Guidelines.

Double dose start for oral PrEP in new EACS guidelines – rapid protection in two hours

26 November 2024. Related: Conference reports, Guidelines, HIV prevention and transmission.

Future PrEP and new results on lenacapavir from PURPOSE 1 and 2 – does HIV exposure explain incident cases?

26 November 2024. Related: Conference reports, HIV prevention and transmission.

Liverpool University Drug Interaction website recognised for global impact on research and care

26 November 2024. Related: Conference reports, PK and drug interactions, Treatment advocacy.

HCV coinfection approaches zero in Spain: but cirrhosis and reinfection among gay men are still significant even with high rates of cure

26 November 2024. Related: Conference reports, Hepatitis coinfection.

Dolutegravir/lamivudine vs triple ART have similar efficacy in advanced HIV infection with CD4 <200 and viral load >100,000

21 November 2024. Related: Conference reports, Antiretrovirals.